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For me, 1967 is a double cen-
tennial year; it commemorates both 
the year of Canadian Federation 
and the first use of nitrites for 
angina pectoris. It was in 1867 
that Lauder Brunton published his 
paper in the Lancet on the use of 
"Nitrite of Amyl for Angina Pec-
toris" (Brunton, 1867). It is sad 
to reflect that apart from this one 
lucky break this is really the only 
significant progress we have made 
in the medical treatment of angina 
pectoris in the last hundred years. 
The reason for this lack of progress 
is that we did not understand why 
nitrites were so beneficial and, con-
sequently, we supplied explanations 
which were incorrect. Having done 
that, we subsequently have tried 
to produce better drugs with the 
same presumed action. When Brun-
ton wrote his paper he deduced 
that the pain of angina was related 
to an elevation of blood pressure. 
He knew that nitrite of amyl could 
produce prostration and a thin 
thready pulse, and he thought it 
probably worked by lowering the 
blood pressure. For some time 
thereafter other drugs that were 
supposed to lower blood pressure 
were given therapeutic trial. Then, 
it was discovered that injection of 
nitrites into the coronary artery of 
an animal caused an increase in 
coronary flow. From this time on 
it was assumed that nitrites re-
lieved angina pectoris by increas-
ing coronary flow. It is for this 
reason that, if you want to look up 
anti-anginal drugs in any contem-
porary textbook, you must look 
them up under the title of "Coro-
nary Vasodilator Drugs." 
For the last 40 years or so man-
ufacturers have continued to pro-
duce more potent vasodilator drugs 
as judged by their ability to in-
crease coronary flow in the normal 
heart. Unfortunately none of them 
has worked. The drug that drew 
my attention to this dilemma is 
one of the most potent of these 
preparations, dipyridamole (Per-
santin). While nitroglycerin pro-
duces only a small increase in 
coronary flow, lasting from 30 sec-
onds to 1 minute, dipyridamole, 
given in a reasonable dose intra-
venously or by mouth, may double 
coronary flow for 20 to 30 min-
utes. It will do this without 
increasing myocardial oxygen con-
sumption, so that the whole myo-
cardium and the coronary sinus 
blood oxygen content increase pro-
portionately. This ought to be 
beneficial if increasing coronary 
flow is going to relieve angina, and 
for this reason we carried out a 
careful clinical trial of this agent 
(Kinsella, Troup, and McGregor, 
1962). We could find no thera-
peutic effect at all. Following this 
experience we decided to pause 
and try to review the patho-physi-
ology of angina and to consider in 
what ways it might theoretically be 
influenced by therapy. 
Pathologic Physiology of 
Angina Pectoris 
Firstly, we now know that an-
gina pectoris is not just a sensation 
of pain and discomfort. It is a 
syndrome which includes not only 
pain, but also electrocardiographic 
changes, a shift to anaerobic me-
77 
tabolism with production of lactate 
and acute left ventricular failure, 
when the involved muscle mass is 
large enough. We also know that 
this syndrome occurs whenever 
there is a discrepancy between the 
demand for myocardial oxygen 
and its supply. This discrepancy 
may, therefore, be correctable by 
reducing oxygen consumption or 
by increasing oxygen supply. 
Normal oxygen supply demands 
fully oxygenated blood and normal 
hemoglobin. When the angina! pa-
tient suddenly gets worse it must 
not necessarily be concluded that 
one of his coronary arteries has 
become occluded, though this may 
of course be occurring. It could 
well be that his hemoglobin has 
dropped due, e.g., to bleeding piles 
or a peptic ulcer. Alternatively he 
may have become anoxemic due 
to pulmonary embolism or pneu-
monia; or he may have inactivated 
up to 20% of his hemoglobin by 
smoking excessively. Likewise, his 
coronary flow may be very de-
pendent on an adequate arterial 
pressure. Thus angina may be pre-
cipitated in the hypertensive pa-
tient with coronary disease by the 
successful treatment of hyperten-
sion. Whenever angina becomes ex-
acerbated, these possibilities should 
be considered first. 
The discrepancy between oxygen 
supply and demand can also be 
influenced, of course, by changes 
in myocardial oxygen consump-
tion. Dr. Richardson (Dr. David 
W., an earlier speaker at the 
symposium) has been telling us 
that the amount of tension de-
veloped by the muscle fiber and 
the rate with which it is developed 
are the two critical determinants 
of oxygen consumption. How-
ever, the tension developed is in-
fluenced by two major variables. 
One is the amount of pressure de-
veloped in the ventricular chamber, 
and the other is the ventricular 
volu.me. According to the rela-
tionship between tension, pressure, 
and radius described by Laplace, 
the tension necessary for each fiber 
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to develop a certain pressure will 
increase with the radius of curva-
ture of the ventricle. A small ven-
tricle can thus produce the same 
pressure with a smaller wall ten-
sion. It is more efficient. All other 
things being equal then, one might 
expect angina to be exacerbated 
by ventricular enlargement and im-
proved by reduction in ventricular 
size. Fear or emotion causing in-
creased sympatho-adrenal activity 
will increase both the force of 
contraction, the rate of develop-
ment of tension, and the heart rate. 
These are good reasons why the 
blocking agent Propranolol, re-
ferred to earlier in this symposium, 
ought to raise the angina! thres-
hold. The disappointing thing is 
how relatively poorly is does work, 
and I think, used at random in an 
angina! population, this drug is 
probably going to have more dan-
gers than benefits. There are 
people, however, such as the thy-
rotoxic and the patient who gets 
pain associated with emotion, in 
whom I suspect this drug will 
prove to be extremely beneficial. 
Mechanism of Action of Nitrites 
Let us now consider the possible 
mechanism of action of the nitrite 
drugs, because these are the only 
really useful group of drugs avail-
able to us. First of all , it is clear 
that they do not just act by re-
lieving pain. They are capable of 
lowering ventricular end-diastolic 
pressure, of abolishing the lactate 
production in the myocardium, and 
of abolishing the electrocardio-
graphic changes of angina. The 
question is how they achieve this 
effect. Theoretically, they might 
either decrease myocardial oxygen 
consumption, or increase oxygen 
supply, or do both at once. 
The prime effect of the nitrites is 
on vascular smooth muscle, and 
they cause an increase in large 
vessel diameter with veno-dilata-
tion. When administered to a rest-
ing subject or to an anesthetized 
animal there is a fall in venous 
pressure, venous return to the 
heart, ventricular volume, cardiac 
output, and blood pressure. As we 
have seen, these effects should re-
duce myocardial oxygen consump-
tion and may well explain the re-
lief obtained by this drug in the 
resting subject. However, nitroglyc-
erin will also produce relief in the 
exercising subject, and it is un-
likely that the same mechanisms 
operate. For example, we have 
found that when patients are cy-
cling on an ergometer a nitroglyc-
erin tablet may actually increase 
the cardiac output, and the hypo-
tensive effect of the drug is almost 
completely abolished (Hoeschen et 
al., 1966). Thus we have turned 
again to the possibility that nitrites 
may indeed exert their effect by 
changing coronary flow. 
Now I would like to distinguish 
carefully between increasing coro-
nary flow in a normal heart and 
re-distributing flow to the most 
ischemic areas of a chronically 
diseased heart. On consideration it 
would seem that the very last drug 
that you would choose to relieve 
angina pectoris is one which in-
creases coronary flow in the normal 
heart. There is already present an 
extraordinarily effective mechanism 
which will increase or reduce coro-
nary flow according to the local 
metabolic need, and as far as we 
can see it is geared very closely 
to oxygen tension. Any substance 
which increases coronary flow in 
the normal heart must do so by 
interfering with this autoregulatory 
mechanism, and it has been shown 
that this mechanism is completely 
paralyzed following a dose of a 
potent vasodilator drug such as 
dipyridamole (Fam and McGregor, 
1967). This cannot be beneficial if 
local hypoxia is already causing 
maximum flow to the most ische-
mic areas of heart muscle. Indeed, 
in the presence of coronary nar-
rowing it might even have an ad-
verse effect by increasing flow to 
non-ischemic areas of heart muscle. 
In atherosclerotic coronary dis-
ease it is the large coronary vessels 
which are narrowed. Studies which 
Dr. W. Fam and I are carrying out 
at present indicate that these ves-
sels take no part in autoregulation. 
Thus to increase flow through 
them it is necessary to use a vaso-
d i lator substance which will act at 
this site in the coronary tree. It 
may well be that the diseased ves-
sels themselves are incapable of 
vasodilatation, but as you well know 
the ischemic areas of muscle may 
be partly or wholly supplied by 
collateral vessels ansmg from 
healthy neighbouring coronary ar-
teries. A drug which acts on these 
arteries may be expected to in-
crease flow into the ischemic areas 
of the heart through collateral 
channels. It is probably significant 
that this is precisely the site of 
action of nitroglycerin. 
Angiographic observation tells us 
that a nitroglycerin tablet will in-
crease the size of all the larger 
coronary arteries for several min-
utes, and we have found that the 
effect of nitroglycerin is almost 
completely confined to the larger 
vessels (McGregor and Fam, 
1966). Furthermore, when a coro-
nary branch of a dog is gradually 
narrowed, thus creating obstruc-
tion, nitroglycerin can be shown to 
augment the collateral flow into the 
ischemic area. Dipyridamole, which 
acts principally on the small coro-
nary vessels does not have this 
effect (Fam and McGregor, 1964). 
Conclusion 
In conclusion I would like to 
stress that these observations do 
not constitute direct evidence of 
the mechanism whereby the nitrites 
relieve angina pectoris. It is prob-
able that they are capable of caus-
ing some reduction of myocardial 
oxygen consumption. However, 
there is increasing indirect evi-
dence which suggests that the site 
of action of these drugs is princi-
pally on the large coronary arter-
ies. Their administration may thus 
relieve coronary spasm, if this ever 
causes angina, and more impor-
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tantly will increase collateral flow 
into ischemic areas of myocardium 
when collateral channels have be-
come enlarged. Drugs such as di-
pyridamole which seem to act on 
the small vessels, which are the site 
of autoregulation, are unlikely to 
have this effect. Indeed, if the au-
toregulatory mechanism is neces-
sary to direct a limited blood flow 
to the most ischemic areas of my-
ocardium, such drugs may theo-
retically be harmful. 
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